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A COMPARISON OF STANDARDS OF DIABETES CARE ACROSS DIFFERENT
RACIAL/ETHNIC GROUPS IN THE UNITED STATES NON-INSTITUTIONALIZED
ADULT POPULATION: A STUDY USING THE 2009-2010 NHANES COHORT
Perez A, Quansah KA, Sanchez J
Nova Southeastern University, Fort Lauderdale, FL, USA
OBJECTIVES:To compare thequality of diabetes care acrossnon-Hispanicwhites and
Blacks and Hispanics in the United States using selected American Diabetes Associa-
tion standards of care. There are few studies using large federal databases evaluating
disparities among racial/ethnic groups in diabetes care. The last one was conducted
using theMedication Expenditure Panel Survey 2000-2001 cohort. This study provides
a more comprehensive assessment of the Standards.METHODS: Data from the Na-
tional Health andNutritional Examination Survey 2009-2010 cohort was used to com-
pare quality markers such as diabetes-related access to care (physician and diabetes
specialists visits), medical care (self-monitoring, treatment, dietary habits, laborato-
ries) and co-morbidities (prevalence, treatment and monitoring) across the racial/
ethnic groups. We used one-way ANOVA and chi-square test to compare continuous
and discrete variables across Whites, Blacks, Hispanics and other. RESULTS: Overall
this group had a mean age of 6114, 51% were male, 60% had no more than a high
school diploma, and 55% had an income$35,000. Only age and education level were
different across groups(p0.05). Average blood pressure and total cholesterol levels
were at goal except for hemoglobin A1c which was 7.3%1.7 and different across
groups(p0.003). We found that the use of insulin, frequency of blood glucose moni-
toring, foot and exam in the last year, nurse educator/nutritionist/dietitian visits, and
diabetic retinopathy, hypertension and hyperlipidemia diagnoses were significantly
different across groups(all p0.05). CONCLUSIONS: A possible relationship between
race/ethnicity and adherence to various standards of diabetes caremay exist. Amore
rigorous epidemiologic study is needed to confirm our findings.
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ESTIMATED PREVALENCE OF HYPOPARATHYROIDISM IN THE UNITED STATES
USING A LARGE CLAIMS DATABASE AND DISEASE SEVERITY FROM PRIMARY
MARKET RESEARCH
Powers J1, Ruscio A2, Saunders B3, Joy K1, Lagast H3
1IMS Health Consulting Group, Alexandria, VA, USA, 2IMS Health Consulting Group, Plymouth
Meeting, PA, USA, 3NPS Pharmaceuticals, Bedminster, NJ, USA
OBJECTIVES: Hypoparathyroidism (HypoPARA) is an endocrine disorder in which
the parathyroid glands produce insufficient parathyroid hormone. This study
aimed to 1) estimate thenumber of insuredHypoPARApatients in theUnited States
(US), and 2) obtain physician assessment of disease severity. METHODS: Preva-
lence was estimated through diagnoses of HypoPARA in the IMS LifeLink Health
Plan Claims Database, containing 60 million unique patients, over a 12-month
period fromOctober 2007 through September 2008, and projected to the US insured
population. Incidence was also calculated by counting the total number of para-
thyroidectomy, thyroidectomy, and neck dissection surgeries in the same data-
base. Surgeries resulting in either transient or chronic (6 months) HypoPARA
were counted to determine proportion of surgeries resulting in HypoPARA. A phy-
sician primarymarket research studywas conducted to assess disease severity and
determine the percentage of newnon-surgical patients. Incidencewas entered into
a model to derive estimated prevalence. RESULTS: The prevalence approach esti-
mated 65,325 insured US HypoPARA patients, of which 90% are chronic. The inci-
dence approach yields 117,342 relevant surgeries resulting in 8,901 cases of Hypo-
PARA over a 12 month period. Overall, 7.6% of surgeries resulted in HypoPARA, of
which 75% are transient and 25% are chronic. When entered into the model, the
estimated prevalence of insured patients is 65,389. The physician market research
found that among all thyroidectomies and parathyroidectomies and neck dissec-
tions performed in a year, 26% resulted in transient HypoPARA and 5% progress to
a chronic state. Of the HypoPARA patients treated over the previous 12 months,
75% were due to surgery. Physicians categorized their patients as 43% mild, 39%
moderate, and 18% severe HypoPARA. CONCLUSIONS: Two methods yielded sim-
ilar estimates of the number of insured HypoPARA patients in the US (65000).
Extrapolated to the US population, the number of HypoPARA patients is estimated
at 78,000.
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PREVENTATIVE STEPS ACROSS PRE-DIABETIC AND DIAGNOSED TYPE 2
DIABETES PATIENTS IN BRAZIL
Gupta S1, Goren A2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA
OBJECTIVES: Risk-factors help identify an increasing number of people as pre-
diabetic, with associated long-term problems to patients during the pre-diabetes
stage; therefore, prevention of early onset of type 2 diabetes (T2D) is essential. To
understand patient utilization of preventative measures, the current study exam-
ined steps taken to prevent diabetes among at-risk Brazilian patients, compared
with diagnosed T2D patients.METHODS: Data were collected from the Brazil 2011
National Health and Wellness Survey, a cross-sectional survey of self-reported
demographics, health outcomes, healthcare attitudes and behaviors among 12,000
adults. Risk of developing diabetes was assessed with the following question: “Has
your doctor told you your blood sugar levels are high, or that you have early dia-
betes or are at risk for developing diabetes?” Respondents answering “yes” and not
already diagnosed with diabetes were classified as pre-diabetics. Self-reported di-
agnosed T2D and pre-diabetics reported on what steps, if any, they took to prevent
diabetes: low fat, low sodium and low sugar diet, regular exercise, and weight loss.
RESULTS: Among 12,000 respondents, the prevalence of T2D and pre-diabetes in
Brazil was 4.0% (n480) and 10.7% (n1,288), respectively. Significant differences
emerged in the use of any preventative steps between T2D (77.9%) and pre-diabetic
(56.7%) patients, p0.001. Diagnosed diabetics were significantly more likely than
pre-diabetics to eat a low fat (44.6% vs. 28.3%, p0.001), low sodium (27.5% vs.
14.6%, p0.001), or low sugar diet (65.0% vs. 42.6%, p0.001), and to attempt weight
loss (35.2% vs. 29.7%, p0.025). No significant differences were found on regular
exercise (28.1% vs. 24.7%) between the groups. CONCLUSIONS: In Brazil, 43.3% of
pre-diabetic patients and 22.1% of diagnosed T2D patients took no preventative
steps, with on average significantly fewer steps taken by pre-diabetics. Measures
ought to be taken to build awareness and encourage lifestyle changes, especially
among patients at high-risk of developing diabetes.
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EVIDENCE LINKING HYPOGLYCEMIC EVENTS TO AN INCREASED RISK OF
DEPRESSION
Shao W, Ahmad R, Khutoryansky N, Aagren M, Bouchard JR
Novo Nordisk, Inc., Princeton, NJ, USA
OBJECTIVES: This retrospective study investigated the association between hypo-
glycemic events (HEs) and depression events (DEs) in patients with diabetes (Type
1 and Type 2).METHODS: Analyzed data were from health care claims for individ-
uals with employer-sponsored primary or Medicare supplemental insurance from
the Thomson Reuters MarketScan database between the years 2008 and 2009. A
baseline period (January 2008 to December 2008) was used to identify eligible pa-
tients and collect baseline clinical and demographic characteristics. Eligible pa-
tients were aged  18 years with diabetes (ICD-9CM codes: 250.00, 250.01, 250.02,
250.03) who had not experienced any HEs, DEs and were not on antidepressant
therapy during the baseline period. An evaluation period (January 2009 to Decem-
ber 2009) was used to identify HEs (ICD-9CM coded: 251.0, 251.1, 251.2, 250.8) and
DEs (ICD-9 CM: 311). A multiple logistic regression model was implemented which
included a binary indicator of HEs and well-known influential covariates such as
age, gender, geography, comorbidity score (Charleson Comorbidity Index) and di-
abetes severity. We studied the relationships between the DEs and HEs before and
after adjusting for the covariates. RESULTS: Of the 923,024 patients meeting the
inclusion criteria 22,735 (2.46%) patients hadHEs and 6,164 (0.67%) patients hadDEs
during the evaluation period. Patients reporting HEs had 78% higher odds of expe-
riencing depression than patients without HEs before adjusting for the covariates.
After adjusting for the covariates data indicated that patients with HEs had similar
higher odds of experiencing depression (OR1.726, 95% CI1.52 – 1.96). Similar
analyses in different age categories showed that the odds ratio monotonically
increases with age. CONCLUSIONS: Results indicate that ICD-9-CM-coded HEs
were associated with an increased risk of DEs in patients with diabetes and the
relative risk increased with the patients’ age.
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DIABETIC KETOACIDOSIS GAP ANALYSIS. POPULATION PERSPECTIVES FROM
LAKE COUNTY, IL, USA
Rasty S1, Dubois M2, Soliman W3
1Roosevelt University, Schuamburg, IL, USA, 2Lake County Department of Public Health,
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OBJECTIVES: In this study we performed Diabetic ketoacidosis (DKA) gap analysis
for the residents of Lake county, IL based on the hospital discharge data collected
between 2001-2009.METHODS: The hospital discharge data between 2001-2009 for
primary discharge diagnosis of DKA was analyzed. All patients ( 4 yr to  85yr )
were categorized in 10 age groups and comparative analysis were performed. Pa-
tient cases for DKAwere identified using ICD-9 codes for DKA (codes 250.10, 250.11,
250.12, 250.13). RESULTS: N 827,355 discharge records were screened. Overall
there were N1788 cases that were discharged with the primary diagnosis of DKA
reflecting a crude rate of 0 .2%. The reported national age –adjusted rate by the CDC
in 2005 was 21.5 cases per 1000 patients (31.6 in  44 y, 3.4 in 45-64y and 1.4 in
patients 65y). There were N933 female and N855 male cases. The overall age-
adjusted rate per 1000 patients was 4.04/ 0.136 cases. Themost frequent length
of stays were 1 day (n288), 2 days (n466), 3 days (n410) or 4 days (N258).
Analysis of data based on residential zip codes ihas identified three suburbs with a
high percentage of Hispanics and blacks with the highest reported cases
(Waukegan 363 cases, Zion 163 cases and North Chicago 109 cases). The over-
all age-adjusted DKA rate in Waukegan was 6.19 / .436 cases per 1000 patients
which is significantly greater than the average calculated rate for residents of Lake
County [OR1.54 (1.40-1.68), P0.0001]. CONCLUSIONS: Data suggests a high rate
of age-adjusted discharge rate for DKA in parts of Lake county, IL. USA, Village of
Waukegan with a large percentage of Hispanic and black population has a signifi-
cantly higher odds of hospital discharge with the diagnosis of DKA compared to
rest of the Lake CTY.
PDB24
PREVALENCE AND INCIDENCE OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS
BASED ON 5.4 MILLION PATIENTS
Wilke T1, Groth A2, Mueller S2, Ahrendt P2, Schwartz D2, Linder R3, Ahrens S3,
Verheyen F3
1Hochschule Wismar, Wismar, Germany, 2IPAM Wismar, Wismar, Germany, 3Scientific Institute
of Techniker Krankenkasse for Benefit and Efficiency in Health Care, Hamburg, Germany
OBJECTIVES: The aims of this contribution are to update andmore precisely quan-
tify the existing data concerning age/gender-specific prevalence and incidence of
type 2 diabetes mellitus (T2DM) in an European setting (Germany). METHODS: To
fulfill the aims of the study, a population-based analysis of the claims data col-
lected by a statutory health insurance fund, and concerning its 5.4 million mem-
bers, was done. A patient was classified as T2DM prevalent if he/she had received
at least one inpatient and/or two outpatient diagnoses of T2DM (ICD10 code E11) in
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two different quarters between 01/01/2006 and 12/31/2008. A patient was consid-
ered to have had new onset T2DM in 2008 under one of three conditions; firstly,
he/she had not received a diagnosis of T2DM in 2006 and 2007; secondly, had not
received oral anti-diabetics in 2006/2007; and thirdly, had received either one in-
patient or two outpatient T2DM diagnosis in 2008. RESULTS: In our sample, a total
of 254,523 patients had T2DM. The prevalence of T2DMwas 4.69 % (women: 3.26%;
men: 6.03%). The average age of these T2DM patients was 64.8 years, and 66.4%
weremale. The incidence of T2DM in our sample was 4.889 cases per 1,000 person-
years in men and 2.863 cases in 1,000 person-years in women. T2DM prevalence/
incidence strongly depended on gender and age. Whereas the T2DM prevalence in
both men and women was below 0.9% in all age groups 40 years, it increased up
to 25.17% (men)/24.34% (women) in the second-highest age group, 85-90 years.
CONCLUSIONS:A comparison of the distribution of AF prevalence/incidence in our
population with that in already published studies shows that our figures are com-
paratively high. Obviously, in a large industrial nation such as Germany, care pro-
vision structures are going to be challenged by the requirement to treatmore T2DM
patients in the future.
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IMPACT OF DIABETES IN PATIENTS HOSPITALIZED FOR PNEUMONIA
Belk KW1, Craver CW2, Blanchette CM3
1MedAssets, Mooresville, NC, USA, 2MedAssets, Huntersville, NC, USA, 3IMS Health Consulting
Group, Alexandria, VA, USA
OBJECTIVES: Previous research has shown patients with diabetes have a higher
risk of death following pneumonia. This study examined the impact of diabetes
diagnosis on in-hospital mortality and length of stay in the inpatient setting.
METHODS: MedAssets health system data (October 2010 to September 2011) were
analyzed for adult inpatients with a principle diagnosis of community-acquired
pneumonia. Cohorts of patientswith andwithout type 2-diabeteswerematched on
age and sex using a propensity score and Greedy matching algorithm. In-hospital
mortality and length of stay were compared between cohorts using multivariate
logistic and negative binomial regression models, respectively, controlling for age,
gender, admission source and type, ventilator use, Deyo-Charlson comorbidity
score, hospital bed size, region, and teaching status. RESULTS: Of 282,474 patients
with pneumonia, approximately 19% had diabetes. Matching resulted in 34,999
patients in each cohort with a mean age of 69 and proportionately more females
than males (51.8% vs. 47.9%). Diabetic patients had higher Deyo-Charlson scores
(3.14 vs. 2.49, p 0.0001) and higher rates of ventilator use (14.1% vs. 10.3%, p
0.0001). Patients diagnosed with diabetes were 26% less likely to die during hospi-
talization (OR  0.74, CI  0.68-0.80). Diabetic patients had a 2% longer length of
stay (IRR  1.02, CI  1.01-1.04). CONCLUSIONS: After controlling for other vari-
ables, patients with type-2 diabetes had a lower risk of in-hospital mortality and
longer length of stay when hospitalized for pneumonia compared to patients with-
out diabetes. Glucose levels at the time of admission and history of diagnosis may
explain some of the association, while care of diabetic patients and residual ben-
efits of other treatments may have reduced the risk of in-inpatient mortality. Fur-
ther studies should assess post-hospitalization outcomes.
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FACTORS ASSOCIATED WITH THREE YEARS OF GOOD OR POOR HEMOGLOBIN
A1C CONTROL AMONG PATIENTS WITH DIABETES
Juarez D1, Sentell T1, Tokumaru S1, Goo R1, Davis J2, Mau M2
1University of Hawaii, Honolulu, HI, USA, 2John A. Burns School of Medicine, Honolulu, HI, USA
OBJECTIVES: To determine which factors were associated with sustained poor or
good glycemic control over three years. METHODS: This retrospective study of
enrollees in a large health plan in Hawaii with diabeteswas restricted to thosewith
poor control at baseline (HbA1c9% in the year 2006), who had HbA1c values for
four years (2006-2009, n2970). Separate multivariable logistic regressions exam-
ined factors related to poor (HbA1c9%) or good (HbA1c7%) control over three
years. Independent variables included age, gender, island of residence, type of
coverage, comorbid conditions, diabetes duration, and number of medications.
RESULTS: Relative to patientswith diabetes duration of a year or less, patientswith
diabetes for8 yearswere significantly less likely to sustain good control [OR0.13,
95%CI(0.09, 0.21)], as were patients with diabetes for 6-7 years [OR0.23,
95%CI(0.13, 0.39)], and 4-5 years [OR0.17, 95%CI(0.09, 0.31)]. Compared to patients
in HMO, patients in PPO or Medicare cost contract were significantly more likely to
have good control. Factors significantly related to poor control were age, diabetes
duration, morbidity level, and number of medications. Relative to patients aged
50-64, younger patients were significantlymore likely to have poor control [age35
OR1.98, 95%CI(1.25, 3.14); age 35-49 OR 1.27, 95%CI(1.03, 1.57)] and older patients
were significantly less likely [age 65-79 OR0.75, 95%CI(0.57, 0.98); age 80
OR0.63, 95%CI (0.41, 0.97)]. Longer diabetes duration and higher morbidity in-
creased the risk of poor control, while patients taking 15medications decreased
the risk. CONCLUSIONS: As diabetes duration strongly predicted poor control, pri-
mary prevention to decrease early onset of diabetes might be a cost-effective
means to reduce the number of patients with poor control. Our findings that
younger patients with diabetes are most likely to have poor control suggest that
interventions need to be targeted to this population.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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SPENDING ON MEDICINES AND INPUTS TO CONTROL DIABETES IN THE STATE
OF MINAS GERAIS. BRAZIL
Souza KM, Figueiredo ACDD, Villela E, Garcia M, Pereira V, Silva L, Souza AL
Health Secretary of Minas Gerais, Brazil, Belo Horizonte, Minas Gerais, Brazil
OBJECTIVES: Diabetes mellitus is a syndrome characterized by chronic hypergly-
cemia with absolute or relative deficiencies of insulin and/or in its action. The
National Health System (SUS), through the pharmaceutical assistancemust ensure
medications and supplies needed for the monitoring of capillary blood glucose of
diabetic patients, defined byministerial decree. The aim of this study is to evaluate
the financial impact of inputs for monitoring capillary blood glucose in relation to
medicinal products for treatment of diabetes mellitus in the state of Minas Gerais
in 2011. METHODS: Survey distribution and financial cost through the computer-
ized management of pharmaceutical assistance (SIGAF) in thez State of Minas
Gerais in 2011 of oral antidiabetics (glibenclamide 5 mg andmetformin hydrochlo-
ride 850mg), human insulinNPHand regular human insulin and indicator strip that
measures the glucose.RESULTS:The costs for regular andNPH Insulin in 2011were
U$8.320.793,31, with oral antidiabetic agents was U$2.032.284,77, as with reagent
strips for monitoring blood glucose level was U$6.978.321,99.The total spending on
drugs for the treatment of diabetesmellituswasU$10.353.078,08. It is observed that
the cost of test strips correspond to approximately 67.5% of this value.
CONCLUSIONS: These results demonstrate that the costs of inputs for monitoring
of blood glucose have a significant financial impact on the State diabetes program.
Moreover, they suggest the need for research regarding the reasonableness of the
use of these inputs by patients. Education strategies, such as the pharmaceutical
guidance for patients who perform self-monitoring blood glucose levels, aid in the
proper use of these inputs and can avoid any waste.
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BUDGET IMPACT ANALYSIS OF NORDITROPIN VERSUS THREE LEADING
MARKET GROWTH HORMONE THERAPIES
Solem CT1, Smith C2, Wiegand P3, Botteman M1, Germak J2, Wisniewski T2
1Pharmerit International, Bethesda, MD, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA,
3Pharmerit North America, LLC., Bethesda, MD, USA
OBJECTIVES: To assess the cost of various market share scenarios of leading re-
combinant human growth hormone (rhGH) pens to a commercial health plan,
taking into consideration drug and wastage costs due to device design.METHODS:
A budget impact model (BIM) was developed to determine the costs of rhGH prod-
ucts. Key model inputs included plan size, number of pediatric and adult patients,
mean [SD] weight, product dosing increments and annual wastage due to pen
devices having varying dosing increments. The BIM included storage and reconsti-
tution wastage as an option. Pediatric (n900) and adult (n100) patient weights
were assumed to be normally distributed with mean (SD) 30.25 (4.00) and 75.00
(2.00) kg. Assumed base case dosages were 0.03 mg/kg daily for pediatric patients;
brand-specific based on product package inserts for adult patients. Market share
was indexed at Year 1 (2011) and presented with 10%, 15% and 20% shifts to Nor-
ditropin from Genotropin, Humatrope, and Nutropin. Costs were based onWAC in
US dollars. RESULTS: Costs per patient per year (PPPY) were higher for Genotropin,
Humatrope and Nutropin vs. Norditropin ranging from approximately $23.1K to
$24.6K in pediatrics and $8.1 K to $9.2K in adults. Norditropin was associated with
the lowest annual milligrams of wastage (9.1 mg pediatric/ 8.5 mg adult, including
wastage due to storage and reconstitution) across all pen dosages, followed by
Nutropin (20.7 mg/ 19.9 mg), Humatrope (20.7 mg/20.2 mg) and Genotropin (30.6
mg/ 30.3 mg). Norditropin remained the least costly per year when: dosing from
package inserts was used, adult dosing was fixed, and when storage and reconsti-
tutionwastage was not included. CONCLUSIONS:Due to differences in cost permg
and wastage associated with design among the leading GH brands on the market,
use of Norditropin pens may result in cost savings.
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A COMPARISON OF THE COSTS FOR TREATING CENTRAL PRECOCIOUS
PUBERTY DURING THE FIRST YEAR WITH LEUPROLIDE ACETATE INJECTIBLE
AND HISTRELIN ACETATE IMPLANT
Banahan BFI1, Mayo K2, Summers KH2
1University of Mississippi, University, MS, USA, 2Endo Pharmaceuticals, Inc., Chadds Ford, PA,
USA
OBJECTIVES: Central precocious puberty (CPP) is generally treated with gonadotro-
pin releasing hormone (GnRH) agonists. The objective was to compare the costs of
first year treatment of monthly leuprolide acetate injections and once-a-year his-
trelin acetate implants. METHODS: Two retrospective cohort studies were con-
ducted using datasets derived from the Thomas Reuter’s MarketScan©Multi-State
Medicaid Database (2003-2007) and the MarketScan© Commercial Database (2005-
2009). Inclusion criteria were 2 claims with target diagnoses occurring 30 or more
days apart, enrollment for 3 months before first treatment, and continuous en-
rollment for 12 months after first treatment. A probabilistic patient flow model
was developed using estimates for treatment patterns and costs for products, office
visits, and monitoring therapy. RESULTS: A total of 4802 Medicaid and 7391 Com-
mercial beneficiaries age 12 years or younger were identified as diagnosed with
CPP. 323 Medicaid and 383 Commercial beneficiaries met the inclusion criteria and
were treated with leuprolide for 365 days or more. Medicaid and Commercial pa-
tients compliant with leuprolide (13 treatments/year) had an average of 14.8 and
14.0 treatments, respectively. Fifty-three percent of Medicaid and 54% of Commer-
cial patients were non-compliant and averaged 9.2 and 7.7 treatments, respec-
tively. Cost for treating 100 patients were simulated using existing levels of non-
compliance and an assumption that all patients should be compliant. Based on
current levels of non-compliance, costs for histrelin implants were 1.9% lower in
Medicaid and 6.5% higher in Commercial plans–however, when based on full com-
pliance, costs for histrelin implants were 12.9% lower in Medicaid and 12.1% lower
in Commercial plans. CONCLUSIONS:With current levels of non-compliance with
GnRH agonists, costs for CPP treatment is similar in Medicaid and slightly less
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